Cargando…

Approaches to interpret the outcomes of a network meta-analysis on comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy

Detalles Bibliográficos
Autores principales:	Jayaraj, Rama, Kumarasamy, Chellan, Sabarimurugan, Shanthi, Samiappan, Suja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489674/ https://www.ncbi.nlm.nih.gov/pubmed/31114370 http://dx.doi.org/10.2147/CMAR.S199442

Ejemplares similares

The Significance of miRNAs as a Prognostic Biomarker for Survival Outcome in T Cell – Acute Lymphoblastic Leukemia Patients: A Systematic Review and Meta-Analysis
por: Sabarimurugan, Shanthi, et al.
Publicado: (2020)

Prognostic miRNA classifiers in t cell acute lymphoblastic leukemia: Study protocol for a systematic review and meta-analysis of observational clinical studies
por: Sabarimurugan, Shanthi, et al.
Publicado: (2019)

Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer—A protocol for systematic review and meta-analysis
por: Kumarasamy, Chellan, et al.
Publicado: (2019)

Commentary: Blood-Derived microRNAs for Pancreatic Cancer Diagnosis: A Narrative Review and Meta-Analysis
por: Jayaraj, Rama, et al.
Publicado: (2019)

Diagnostic and prognostic value of microRNAs for cancers- strategies and approaches to improve the clinical utility
por: Jayaraj, Rama, et al.
Publicado: (2019)

Systematic review and meta-analysis of prognostic microRNA biomarkers for survival outcome in nasopharyngeal carcinoma
por: Sabarimurugan, Shanthi, et al.
Publicado: (2019)

Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies
por: Sabarimurugan, Shanthi, et al.
Publicado: (2019)

Comparative efficacy of different targeted therapies plus fulvestrant for advanced breast cancer following progression on prior endocrine therapy: a network meta-analysis
por: Zhang, Tingting, et al.
Publicado: (2018)

A comparison of fulvestrant plus a targeted agent with fulvestrant alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: a meta-analysis
por: Xu, Liang, et al.
Publicado: (2018)

Meta-analysis of the prognostic role of HE4 expression in cancer patients: clinical insights into interpretation of clinical outcomes
por: Jayaraj, Rama, et al.
Publicado: (2019)

Systematic review and meta-analysis of cancer studies evaluating diagnostic test accuracy and prognostic values: approaches to improve clinical interpretation of results
por: Jayaraj, Rama, et al.
Publicado: (2018)

Comment on “Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis”
por: Jayaraj, Rama, et al.
Publicado: (2019)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Prognostic Value of miRNAs in Head and Neck Cancers: A Comprehensive Systematic and Meta-Analysis
por: Kumarasamy, Chellan, et al.
Publicado: (2019)

Diagnostic and prognostic role of HE4 expression in multiple carcinomas: A protocol for systematic review and meta-analysis
por: Kumarasamy, Chellan, et al.
Publicado: (2019)

Comment on “Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer”
por: Jayaraj, Rama, et al.
Publicado: (2018)

Comment on ‘Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis’
por: Jayaraj, Rama, et al.
Publicado: (2018)

Letter to the editor regarding the publication “Association between matrix-metalloproteinase polymorphisms and prostate cancer risk: a meta-analysis and systematic review”
por: Jayaraj, Rama, et al.
Publicado: (2019)

miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis
por: Madurantakam Royam, Madhav, et al.
Publicado: (2019)

Clinical Theragnostic Relationship between Drug-Resistance Specific miRNA Expressions, Chemotherapeutic Resistance, and Sensitivity in Breast Cancer: A Systematic Review and Meta-Analysis
por: Jayaraj, Rama, et al.
Publicado: (2019)

Prognostic value of microRNAs in head and neck cancers: a systematic review and meta-analysis protocol
por: Kumarasamy, Chellan, et al.
Publicado: (2018)

Letter to the editor “Prognostic value of microRNAs in colorectal cancer: a meta-analysis”
por: Jayaraj, Rama, et al.
Publicado: (2018)

Conceptual interpretation and clinical applicability of a systematic review and meta-analysis about prognostic value of apolipoproteins in COVID-19 patients
por: Rajagopal, Mogana, et al.
Publicado: (2022)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
por: Bachelot, Thomas, et al.
Publicado: (2013)

Clinical Theragnostic Relationship between Chemotherapeutic Resistance, and Sensitivity and miRNA Expressions in Head and Neck Cancers: A Systematic Review and Meta-Analysis Protocol
por: Shaw, Peter, et al.
Publicado: (2021)

Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real‐world study for patients with hormone receptor‐positive and HER2‐negative advanced breast cancer
por: Zhao, Yannan, et al.
Publicado: (2020)

Clinical and conceptual approaches to interpreting the findings of systematic review and meta-analysis of mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease
por: Jayaraj, Rama, et al.
Publicado: (2020)

Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis
por: Shaw, Peter, et al.
Publicado: (2022)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Combined chemo-endocrine therapy as a potential new option for HR+/HER2− advanced breast cancer: a prospective study of fulvestrant plus oral vinorelbine
por: Wang, Xue, et al.
Publicado: (2023)

Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials
por: Vergote, I, et al.
Publicado: (2004)

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial
por: Tibau, Ariadna, et al.
Publicado: (2023)

Letter to the editor: is HIF-1α a viable prognostic indicator in OSCC? A critical review of a meta-analysis study
por: Jayaraj, Rama, et al.
Publicado: (2018)

Clinical and conceptual comments on “Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis”
por: Jayaraj, Rama, et al.
Publicado: (2020)

Clinical comments on “Mental disorder prevalence among populations impacted by coronavirus pandemics: A multilevel meta-analytic study of COVID-19, MERS & SARS”
por: Jayaraj, Rama, et al.
Publicado: (2021)

Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(−) breast cancer that had progressed during or after prior endocrine therapy
por: Musolino, Antonino, et al.
Publicado: (2017)

Fulvestrant in advanced breast cancer: evidence to date and place in therapy
por: Boér, Katalin
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_46gqt2lctqrduonvl3h6gtuvee